Ocumension Therapeutics (1477.HK)

HKD 5.55

(0.36%)

Revenue Summary of Ocumension Therapeutics

Ocumension Therapeutics's latest annual revenue in 2023 was 246.36 Million CNY , up 54.99% from previous year.
Ocumension Therapeutics's latest quarterly revenue in 2023 FY was 246.36 Million CNY , up 54.99% from previous quarter.
Ocumension Therapeutics reported a annual revenue of 158.95 Million CNY in annual revenue 2022, up 183.11% from previous year.
Ocumension Therapeutics reported a annual revenue of 56.14 Million CNY in annual revenue 2021, up 328.73% from previous year.
Ocumension Therapeutics reported a quarterly revenue of 71.33 Million CNY for 2023 Q4, down 0.0% from previous quarter.
Ocumension Therapeutics reported a quarterly revenue of 246.36 Million CNY for 2023 FY, up 54.99% from previous quarter.

Annual Revenue Chart of Ocumension Therapeutics (2023 - 2018)

Historical Annual Revenue of Ocumension Therapeutics (2023 - 2018)

Year	Revenue	Revenue Growth
2023	246.36 Million CNY	54.99%
2022	158.95 Million CNY	183.11%
2021	56.14 Million CNY	328.73%
2020	13.09 Million CNY	6792.63%
2019	190 Thousand CNY	0.0%
2018	- CNY	0.0%

Year	Revenue	Revenue Growth
2023 Q2	51.84 Million CNY	0.0%
2023 Q4	71.33 Million CNY	0.0%
2023 FY	246.36 Million CNY	54.99%
2023 Q1	51.84 Million CNY	-0.7%
2023 Q3	71.33 Million CNY	37.59%
2022 Q1	27.26 Million CNY	54.3%
2022 Q2	27.26 Million CNY	0.0%
2022 Q4	52.21 Million CNY	0.0%
2022 Q3	52.21 Million CNY	91.48%
2022 FY	158.95 Million CNY	183.11%
2021 Q1	10.4 Million CNY	86.67%
2021 FY	56.14 Million CNY	328.73%
2021 Q4	17.67 Million CNY	0.0%
2021 Q3	17.67 Million CNY	69.89%
2021 Q2	10.4 Million CNY	0.0%
2020 Q3	5.57 Million CNY	470.9%
2020 Q2	976 Thousand CNY	0.0%
2020 FY	13.09 Million CNY	6792.63%
2020 Q1	976 Thousand CNY	927.37%
2020 Q4	5.57 Million CNY	0.0%
2019 Q3	95 Thousand CNY	0.0%
2019 FY	190 Thousand CNY	0.0%
2019 Q4	95 Thousand CNY	0.0%
2019 Q1	- CNY	0.0%
2019 Q2	- CNY	0.0%
2018 FY	- CNY	0.0%

Peer Revenue Comparison of Ocumension Therapeutics

Name	Revenue	Revenue Difference
Uni-Bio Science Group Limited	484.71 Million HKD	49.173%
CK Life Sciences Int'l., (Holdings) Inc.	5.32 Billion HKD	95.371%